Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 59 minutes ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $39 to $42.
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $39 to $42.